Business Wire

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Del

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of five new global grants programs to continue to support investigator-sponsored research in chronic hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV and HIV co-infection, nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). The programs will accept applications from around the world for projects that seek to address pressing unmet patient needs in liver disease, including improving screening and linkage to care, simplifying HCV testing and treatment, developing innovative referral pathways to help patients with NASH access care, addressing gaps in HBV care for special populations and understanding PSC epidemiology.

“It takes more than medicine alone to improve the lives of people living with liver diseases. In HCV, understanding optimal ways to simplify testing and treatment is critical to reaching diverse populations living with the disease. People living with NASH need to access earlier diagnoses and clearer referral pathways to help them access care,” said Bill Guyer, Senior Vice President, Head of Medical Affairs, Gilead Sciences. “Gilead is proud to support investigator-sponsored research areas across liver diseases, which we believe can help broaden understanding of how to manage these diseases and help patients be appropriately linked to care.”

The new grant programs are:

  • HCV STAT (Simplification and Test and Treat Strategies toward HCV Elimination)
    This program will fund approximately fifteen projects with a total commitment of US $10M focused on simplifying HCV care delivery and implementing test and treat strategies to overcome barriers to patient care. Applications will be accepted from April 11 to June 30, 2019.

    STAT is the latest addition to the LEGA-C platform, “Local Elimination Programs Leading to Global Action in HCV” and includes the ongoing programs CITE, SCALE, CHIME, and NoCo. To date, Gilead has committed $50M to support 79 elimination projects around the world through LEGA-C.
  • HIV/HCV NoCo (No Co-Infection)
    In the third installment of NoCo, this program will fund approximately six to eight projects with a total commitment of US $3M focused on investigating strategies to link patients living with HCV and HIV co-infection to HCV treatment. Applications will be accepted from May 1 to June 14, 2019.
  • NASH Models of Care
    This program will fund approximately eight to ten projects with a total commitment of US $4M focused on investigating care pathways between multidisciplinary providers for screening, identifying, and helping to refer high-risk patients living with NASH to appropriate medical care. Applications will be accepted from June 3 to July 15, 2019.
  • HBV CARE (Linkage to CARe & Epidemiology in Special Populations)
    This program will fund approximately six projects with a total commitment of US $1M focused on improving linkage to care among underserved population and analyzing or identifying data gaps in HBV epidemiology in specific demographics or geographies. Applications will be accepted from August 1 to September 15, 2019.
  • PSC PACE (PrimAry Sclerosing Cholangitis Epidemiology)
    This program will fund up to five projects with a total commitment of US $1M focused on identifying gaps in PSC epidemiology data and improving understanding of the cascade of care. Applications will be accepted from September 16 to October 11, 2019.

For more information on Gilead’s new liver disease grants programs, please visit https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Sung Lee, Investors
(650) 524-7792

Arran Attridge, Media
(650) 425-8975

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ABS, Google Cloud and SoftServe Partner to Demonstrate Feasibility of AI-enabled Corrosion Detection24.4.2019 15:57:00 CESTPressemelding

ABS, Google Cloud and SoftServe completed a pilot project applying artificial intelligence (AI) models to detect levels of corrosion and coating breakdown on ships and offshore structures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005822/en/ ABS, Google Cloud and SoftServe Partner to Demonstrate Feasibility of AI-enabled Corrosion Detection (Photo: Business Wire) The project successfully demonstrated the accuracy of AI in detecting and assessing structural anomalies commonly found during visual inspection. AI techniques could be further used to analyze images over time to understand corrosion and coating breakdown trends. “Digital innovation in AI will change how surveys and maintenance strategies are executed, driving more condition-based approaches to class and maintenance,” said ABS Chairman, President and CEO, Christopher J. Wiernicki. “We are building a future in which digital tools can remotely assess the co

The 2019 .eu Web Awards Launch Today24.4.2019 14:13:00 CESTPressemelding

The .eu Web Awards is an online competition designed to acknowledge the best websites using the .eu or .ею extensions in five diverse categories. Anyone who is eligible according to the .eu Web Awards rules can nominate their favourite .eu or .ею. website. This includes .eu and .ею domain name holders themselves, who can nominate their very own website for participation in the .eu Web Awards. “After the successful edition of 2018 with 130 nominations and nearly 10 000 votes for excellent sites, we look forward to awarding the best websites in the five categories”- Giovanni Seppia, EURid External Relations Manager. The 15 finalists will be invited to the .eu Web Awards gala in Brussels on 20 November 2019 where the five winners – one per category – will be announced. The winners will receive a prestigious award package, including a two-month billboard advertising campaign in Brussels Airport, a custom video produced by EURid for their promotional purposes, and a custom trophy and person

The Valence Group Advises INEOS on Its Sale of INEOS Melamines and Paraform to Prefere Resins Holding GmbH24.4.2019 13:54:00 CESTPressemelding

The Valence Group Advises INEOS Enterprises, a division of INEOS (“INEOS”), on its sale of INEOS Melamines and Paraform to Prefere Resins Holding GmbH. The Valence Group acted as financial advisor to INEOS Enterprises on its announced sale of INEOS Melamines & Paraform to Prefere Resins Holding GmbH. The agreement covers sites in USA, Germany and Indonesia. INEOS Paraform is Europe’s second largest producer of Paraformaldehyde. INEOS Melamines is a world leader in the supply of melamine resins into coatings, paper, textile, tyre, rubber, and decorative laminates industries. Financial terms of the transaction were not disclosed. About The Valence Group The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors. The Valence Group team includes a unique combination of professionals with backgrounds in investment banking and strategy consulting within the chemicals and materials ind

Centreon EMS Removes IT Monitoring Blind Spots between Hybrid, Multi-Cloud and Physical Networks24.4.2019 13:19:00 CESTPressemelding

Centreon, a trusted provider of enterprise monitoring solutions for converging and hybrid IT infrastructures, today rolled out a new release of Centreon EMS, its flagship, end-to-end IT monitoring platform. The new release provides ITOps with holistic and contextual insights, through the integrations needed for today’s distributed, on-premise and multi-cloud - public, private and container - environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005610/en/ Credits: GIF file of Centreon GeoViews. Centreon’s EMS 19.04 release offers ITOps managing a host of legacy assets but now contending with increased cloud workloads and growing networks of connected objects, the integrated visibility needed to ensure end-to-end performance across diverse IT environments. This expanded functionality reduces costs and complexity, aggregating data from across the entire IT infrastructure into a single, holistic view of the various

Neustar Research Shows Large Attacks Growing as Multi-Vector Exploits Increasingly Become the Norm24.4.2019 13:00:00 CESTPressemelding

Neustar, Inc., a trusted, neutral provider of real-time information services, today released its Q1, 2019 Cyber Threats and Trends report which highlights new areas of growth in Distributed Denial of Service (DDoS) attacks over the past year. The report affirms that DDoS attacks continue to be an effective means to distract and confuse security teams while inflicting serious damage to brands. The report reveals that while volumetric attacks over 50Gbps remain a relatively small segment of the overall threat picture at only 12% of attacks, their frequency has grown enormously when compared to the same period in 2018. The latest attacks morph over the course of the attack using a variety of ports and protocols to locate and exploit vulnerabilities. In Q1, 2019, over 77% of attacks used two or more vectors. In particular, the trend of targeting subnets and classless inter-domain routing (CIDR) blocks to slow or stop network traffic across the internet is a disruptive DDoS threat, identifi

Seoul Semiconductor Continues Enforcement against Infringement of Its LED Driver Patents24.4.2019 13:00:00 CESTPressemelding

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it has filed another patent infringement lawsuit for infringement of its LED driver patents, this time against SATCO Products, Inc. (“SATCO”). In its complaint, Seoul asserts that SATCO is selling various LED lighting products that infringe “eleven” (11) of Seoul’s patents covering LED driver technology, including U.S. Patent 7,081,722, U.S. Patent 9,807,828; U.S. Patent 8,513,899; and U.S. Patent 8,716,946. The asserted LED driver patents are widely used in replacement bulbs in the form of incandescent or fluorescent lamps, wall-mount lights, and ceiling lights. The patented technology covers products with a linear driver for directly operating LEDs under household voltage, a step operation driver for generating flicker-free lights, as well as a dimmable driver for realizing smart lighting. Seoul has successfully enforced its LED driver patents in several